V
Ventyx Biosciences, Inc. (VTYX)
14.00
0.00 (0.00%)
Get all premium features to the best stock analysis tool
14.00
0.00 (0.00%)
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn’s disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson’s disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
| Name | Position |
|---|---|
| Dr. Sheila K. Gujrathi M.D. | Executive Chairperson |
| Ms. Arline Nakanishi | Senior Vice President of Biometrics |
| Ms. Kathy Ogilvie Ph.D. | Senior Vice President of Translational & Nonclinical Research |
| Ms. Snehal Naik Ph.D. | Senior Vice President of Clinical Development |
| Date | Type | Document |
|---|---|---|
| 2026-03-04 | 8-K | d116049d8k.htm |
| 2026-03-03 | 8-K | d53134d8k.htm |
| 2026-02-02 | DEFM14A | d93324ddefm14a.htm |
| 2026-01-22 | PREM14A | d93324dprem14a.htm |
| 2026-01-08 | DEFA14A | d11725ddefa14a.htm |
| 2026-01-07 | 8-K | d98679d8k.htm |
| 2025-11-06 | 8-K | vtyx-20251106.htm |
| 2025-10-22 | 8-K | d98315d8k.htm |
| 2025-08-07 | 10-Q | vtyx-20250630.htm |
| 2025-06-17 | 8-K | vtyx-20250617.htm |